A Novel Vascular Endothelial Growth Factor trap KP-VR2
with Enhanced Ligand Blocking
Volume 4 - Issue 4
VM.Molina*1, J. Morales, MF1, Gutierrez2,3
- 1Boehringer Ingelheim, Pet Technical Service, Colombia
- 2Clinic veterinary Campomaskotas. Colombia
- 3University of La Salle, Colombia
Received:March 03, 2021 Published: April 26, 2021
Corresponding author: VM. Molina, Boehringer Ingelheim, Pet Technical Service, Colombia
DOI: 10.32474/OAJOM.2021.04.000191
Fulltext
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
Antiangiogenic therapies targeting vascular endothelial growth factor (VEGF)-A have been commonly used to treat various
cancers; however, their clinical efficacy remains limited due to resistance and activation of compensatory pathways resulting from
elevated circulating VEGF-B and placental growth factor (PlGF) levels. Thus, we developed a novel VEGF-Trap, KP-VR2, which can
neutralize VEGF-A, VEGF-B, and PlGF to mediate these problems. KP-VR2 consists of two consecutive second Ig-like domains (D2s)
of VEGF receptor 1 (VEGFR-1) fused to human IgG1 Fc. KP-VR2 showed more potent decoy activity than the current VEGF-Trap
against VEGF and PlGF. Most importantly, two consecutive D2s of VEGFR-1 can generate two putative binding sites, resulting in a
significant improvement in binding capacity. These advances resulted in stronger antitumor efficacy in implanted tumor models
than aflibercept and bevacizumab. Overall, the results of this study highlight KP-VR2 as a promising therapeutic candidate for
further clinical drug development.
Abstract|
Introduction|
Results|
Discussion|
Experimental Procedures|
Statistical Analyses|
Data Availability Statement|
Acknowledgements|
Conflict of Interest|
References|